CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

Speciality: Oncology

Description:

Welcome to this insightful panel discussion featuring renowned experts Dr. Srinivas K G and Dr. Abhaya Kumar S M, as they delve into the transformative role of CDK4/6 inhibitors in redefining treatment for HR+/HER2- advanced breast cancer (aBC) in post-menopausal women. The discussion explores the latest clinical evidence, real-world efficacy, and the evolving treatment paradigm that has significantly improved outcomes for patients. The experts share their perspectives on optimal therapeutic strategies, patient selection, and overcoming resistance, making this a must-watch for oncologists and healthcare professionals. 

The panel highlights key advancements in targeted therapies, emphasizing how CDK4/6 inhibitors have become a cornerstone in managing HR+/HER2- aBC. Dr. Srinivas and Dr. Abhaya discuss comparative efficacy, safety profiles, and combination approaches with endocrine therapy, providing valuable insights for clinical decision-making. They also address challenges such as treatment sequencing, managing adverse effects, and future directions in breast cancer research, offering a comprehensive overview of current best practices. 

As the conversation concludes, the experts underscore the importance of personalized medicine and ongoing research to further enhance patient survival and quality of life. This engaging discussion serves as an essential resource for medical professionals seeking to stay updated on breast cancer therapeutics. Don’t miss this opportunity to gain expert insights, watch the full discussion now and stay tuned for more informative sessions from leading specialists in oncology.
 

See More Webinars @ Hidoc Webinars